Dr. Greenbaum works with the Experimental Medicine Unit (EMU) at BRI to understand the biology behind experimental therapies. Most of these studies focus on type 1 diabetes (T1D). Some of the research projects our group has investigated in collaboration with the EMU include:
- Siltuximab and Tocilizumab in T1D
- AIRmax as a measure of functional beta cell mass in at-risk individuals for T1D
- Defining early markers of response to Abatacept in new onset T1D
- Kinetics of immune cell turnover
- Longitudinal evaluation of immune biomarkers in T1D, T2D
Additional Research Projects
Collaborations with Industry Partners to test new T1D therapies
The Greenbaum Lab collaborates with industry partners to test new T1D therapeutics, often involving multi-site phase 2 and phase 3 randomized clinical trials with the goal of understanding the efficacy of new therapies.
Immune Tolerance Network (ITN) clinical trials in type 1 diabetes
In collaboration with the Immune Tolerance Network, our group conducts studies to understand the ways T1D therapies promote immune tolerance and to identify biomarkers associated with immune tolerance.
TrialNet clinical trials in those at risk of type 1 diabetes
We are deeply engaged in TrialNet studies and science, including our ongoing Pathway to Prevention trial that screens family member of T1D patients for T1D risk and the successful Teplizumab Prevention Trial.
